Biodesix (BDSX) Stock Forecast & Price Target

Biodesix is a diagnostic solutions company with a focus on lung disease, providing diagnostic testing services as well as companion diagnostics for biopharmaceutical companies. BDSX expects to achieve positive adjusted EBITDA in the near term, and with a solid revenue growth and a defensible, near-monopoly position in blood-based nodule risk assessment, we believe the company has a strong growth potential. Biodesix has a strong IP library and a differentiated three-test blood-based suite for NSCLC treatment guidance, with an average TAT of 3 days. We maintain our BUY rating and a price target of $20.

Biodesix is positioned in a growing market and has unique biopharmaceutical partnerships, but there is significant impetus to prove their viability. The company’s growing volume is a tailwind for new products, but competition in the market may hinder future expansion. Additionally, the company's history of significant net losses and ongoing reliance on equity issuance could pose challenges in reaching long-term profitability.